Document Detail


Therapeutic advances in pancreatic cancer.
MedLine Citation:
PMID:  23622141     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Despite our improved understanding of pancreatic cancer biology and ability to perform more complex pancreatic cancer surgeries that produce better short-term outcomes, major progress toward increasing survival times has been painstakingly slow. Through the often-repeated, dismal survival statistics, it is easy to lose sight of real progress that has been made in pancreatic cancer therapy. It is particularly interesting to observe the extent to which these advances are interdependent and the effects they have had on practice. For example, during the past 5-10 years, we have seen widespread adoption of pancreatic imaging protocols that allow for objectively defined criteria of resectability. This has led to the definition of "borderline resectable pancreatic cancer"--a new clinical category that has affected the design of clinical trials. A major change in our surgical approach has been the move to minimally invasive pancreatectomy, which continues to gain broader acceptance and use, particularly for left-sided lesions. Although many new agents have been developed aimed at putative molecular targets, recent breakthroughs in therapy for advanced disease have arisen from our ability to safely give patients combination cytotoxic chemotherapy. We are now faced with the challenge of combining multidrug, cytotoxic chemotherapies with newer-generation agents. Ultimately, the hope is that drug combinations will be selected based on biomarkers, and strategies for pancreatic cancer therapy will be personalized, which could prolong patients' lives and reduce toxicity. We review the major advances in pancreatic cancer therapy during the last 5 years, and discuss how these have set the stage for greater progress in the near future.
Authors:
Andrew Scott Paulson; Hop S Tran Cao; Margaret A Tempero; Andrew M Lowy
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Gastroenterology     Volume:  144     ISSN:  1528-0012     ISO Abbreviation:  Gastroenterology     Publication Date:  2013 Jun 
Date Detail:
Created Date:  2013-04-29     Completed Date:  2013-06-20     Revised Date:  2013-10-28    
Medline Journal Info:
Nlm Unique ID:  0374630     Medline TA:  Gastroenterology     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1316-26     Citation Subset:  AIM; IM    
Copyright Information:
Copyright © 2013 AGA Institute. Published by Elsevier Inc. All rights reserved.
Affiliation:
University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California 94115, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antineoplastic Combined Chemotherapy Protocols / adverse effects,  therapeutic use*
Chemoradiotherapy, Adjuvant
Chemotherapy, Adjuvant
Diagnostic Imaging / methods
Humans
Neoadjuvant Therapy
Pancreatectomy* / adverse effects
Pancreatic Neoplasms / diagnosis,  mortality,  therapy*
Predictive Value of Tests
Radiotherapy, Adjuvant
Surgical Procedures, Minimally Invasive
Treatment Outcome
Comments/Corrections
Erratum In:
Gastroenterology. 2013 Sep;145(3):694

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Pancreatic cystic neoplasms: management and unanswered questions.
Next Document:  Global remodeling of nucleosome positions in C. elegans.